SCHEMBL6319663

SCHEMBL6319663

CCC(N)COCC(=O)N(C)[C@H](Cc1csc2ccccc12)C(=O)N(C)[C@H](Cc1ccc(OC)cc1)C(=O)NC

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 6/20 0.40
KLK1 P06870 4/20 0.40
OPRD1 P41143 3/20 0.36
OPRM1 P35372 2/20 0.36
OPRK1 P41145 2/20 0.36
MMP2 P08253 2/20 0.35
MMP9 P14780 2/20 0.35
MMP8 P22894 2/20 0.35
TACR1 P25103 1/20 0.34
MMP1 P03956 3/20 0.32
KLK7 P49862 1/20 0.32
TP53 P04637 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
CTSL P07711 1/20 0.32
CTSS P25774 1/20 0.32
CTSK P43235 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317679 0.93 MMP2 (0.37) KLKB1KLK1OPRD1OPRM1OPRK1
SCHEMBL6318207 0.89 KLKB1 (0.39) KLKB1KLK1OPRD1OPRM1OPRK1
SCHEMBL6323433 0.87 MMP2 (0.36) KLKB1KLK1OPRD1OPRM1OPRK1
SCHEMBL6318098 0.86 MMP2 (0.36) KLKB1KLK1OPRD1OPRM1OPRK1
SCHEMBL8918072 0.86 KLKB1 (0.34) KLKB1KLK1OPRD1OPRM1OPRK1
SCHEMBL6324563 0.86 MMP3 (0.43) KLKB1KLK1MMP2MMP9MMP1
SCHEMBL6316746 0.84 MMP1 (0.41) MMP9TACR1MMP1CTSLCTSS
SCHEMBL6326078 0.83 S1PR1 (0.39) KLKB1KLK1MMP2MMP9MMP8
SCHEMBL6316613 0.82 KLKB1 (0.34) KLKB1KLK1OPRD1OPRM1OPRK1
SCHEMBL6324008 0.81 CTSL (0.39) KLKB1KLK1OPRD1OPRM1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US claimed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US claimed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP claimed
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 KLKB1 988/4885KLK1 802/4885OPRD1 484/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR KLKB1 1152/4885KLK1 838/4885OPRD1 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.